Diabetes mellitus and cardiac function

Mahgoub, Mahmoud A.; Abd‐Elfattah, Anwar S.

doi:10.1007/978-1-4615-5687-9_6

Cited by 60 publications

(59 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prospective studies [22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] indicate that all of the major cardiovascular risk factors-cigarette smoking, hypertension, and high serum cholesterol-continue to act as independent contributors to CVD in patients with diabetes. As already mentioned, clustering of metabolic risk factors, called the metabolic syndrome, occurs commonly in type 2 diabetes.…”

Section: Covariate Risk Factorsmentioning

confidence: 99%

Diabetes and Cardiovascular Disease

Grundy¹,

Benjamin²,

Burke³

et al. 1999

Circulation

1,850

531

View full text Add to dashboard Cite

Section: Covariate Risk Factorsmentioning

confidence: 99%

Diabetes and Cardiovascular Disease

Grundy¹,

Benjamin²,

Burke³

et al. 1999

Circulation

1,850

531

View full text Add to dashboard Cite

“…The effect of diabetes on the heart is multifactorial (Mahgoub et al 1998,McNeill et al 1986,Poornima et al 2006. In general, the diagnosis of diabetic cardiomyopathy is based on impairment of LVEF.…”

Section: Discussionmentioning

confidence: 99%

“…Diabetic cardiomyopathy is characterized clinically by ventricular hypertrophy and impaired diastolic function, which may precede the onset of systolic dysfunction (Borbély et al 2005,Dent et al 2001,Dhalla et al 1998,Dhalla et al 1985,Gustafsson et al 2001,Mahgoub et al 1998,McNeill et al 1986,Riordan et al 2005. However, while diabetes is associated with altered cellular structure and extracellular matrix disorganization (Thompson 1994), the effects of such physiologic alterations on diastolic function have not been fully characterized prior to the overt manifestation of diabetic cardiomyopathy, particularly in the setting of normal left ventricular ejection fraction (LVEF).…”

Section: Introductionmentioning

confidence: 99%

The Kinematic Filling Efficiency Index of the Left Ventricle: Contrasting Normal vs. Diabetic Physiology

Zhang

Chung

Riordan

et al. 2007

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

An index of filling efficiency incorporating stiffness and relaxation (S&R) parameters has not been derived or validated although numerous studies have focused on the effects of altered relaxation or stiffness on early rapid filling and diastolic function. Previous studies show that S&R parameters can be obtained from early rapid filling (Doppler E-wave) via kinematic modeling. E-wave contours are governed by harmonic oscillatory motion, modeled via the parameterized diastolic filling (PDF) formalism. The previously validated model determines three (unique) oscillator parameters from each E-wave having established physiologic analogues: x o (load), c (relaxation/viscoelasticity), and k (chamber stiffness). We define the dimensionless, filling-volume based kinematic filling efficiency index (KFEI) as the ratio of the velocity-time integral (VTI) of the actual clinical E-wave contour fit via PDF to the VTI of the PDF model-predicted ideal E-wave contour having the same x o and k, but with no resistance to filling (c=0). To validate the new index, Doppler E-waves from 36 subjects with normal ventricular function, 17 diabetic and 19 well-matched non-diabetic controls, were analyzed. E-wave parameters x o , c, and k and KFEI were computed for each subject and compared. In concordance with prior human and animal studies in which c differentiated between normal and diabetic hearts, KFEI differentiated (p<0.001) between non-diabetics (55.8±3.3%) and diabetics (49.1±3.3%). Thus, the new index introduces and validates the concept of filling efficiency, and using diabetes as a working example, provides quantitative and mechanistic insight into how S&R affects ventricular filling efficiency.

show abstract

“…Mig-6 is an adaptor molecule containing a CRIB domain, a src homology 3 (SH3) binding domain, a 14-3-3 binding domain, and an epidermal growth factor receptor (EGFR) binding domain (19,20). Sustained Mig-6 expression is thought to trigger cells to initiate hypertrophy in chronic pathological conditions, such as diabetes and hypertension (21,22). Ablation of Mig-6 in mice has led to the development of animals with epithelial hyperplasia, adenoma, and adenocarcinomas in organs, such as the lung, gallbladder, and bile duct (23,24).…”

mentioning

confidence: 99%

Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease

Jeong

Lee

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

118

View full text Add to dashboard Cite

Normal endometrial function requires a balance of progesterone (P4) and estrogen (E2) effects. An imbalance caused by increased E2 action and/or decreased P4 action can result in abnormal endometrial proliferation and, ultimately, endometrial adenocarcinoma, the fourth most common cancer in women. We have identified mitogen-inducible gene 6 (Mig-6) as a downstream target of progesterone receptor (PR) and steroid receptor coactivator (SRC-1) action in the uterus. Here, we demonstrate that absence of Mig-6 in mice results in the inability of P4 to inhibit E2-induced uterine weight gain and E2-responsive target genes expression. At 5 months of age, the absence of Mig-6 results in endometrial hyperplasia. Ovariectomized Mig-6 d/d mice exhibit this hyperplastic phenotype in the presence of E2 and P4 but not without ovarian hormone. Ovariectomized Mig-6 d/d mice treated with E2 developed invasive endometrioid-type endometrial adenocarcinoma. Importantly, the observation that endometrial carcinomas from women have a significant reduction in MIG-6 expression provides compelling support for an important growth regulatory role for Mig-6 in the uterus of both humans and mice. This demonstrates the Mig-6 is a critical regulator of the response of the endometrium to E2 in regulating tissue homeostasis. Since Mig-6 is regulated by both PR and SRC-1, this identifies a PR, SRC-1, Mig-6 regulatory pathway that is critical in the suppression of endometrial cancer.estrogen ͉ endometrial cancer ͉ progesterone ͉ progesterone receptor ͉ SRC-1

show abstract

Diabetes mellitus and cardiac function

Cited by 60 publications

References 28 publications

Diabetes and Cardiovascular Disease

Diabetes and Cardiovascular Disease

The Kinematic Filling Efficiency Index of the Left Ventricle: Contrasting Normal vs. Diabetic Physiology

Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease

Contact Info

Product

Resources

About